Objective: To assess platelet activating factor (PAF) antagonists, potent neuroprotective agents in experimental cerebral dysfunction, in clinical practice.
Design: Double blind, minimised, placebo controlled trial of low and high dose PAF antagonist (lexipafant).
Setting: Cardiac surgery unit.
Patients: 150 patients undergoing coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass.
Interventions: Randomisation to placebo, low dose (10 mg) or high dose (100 mg) lexipafant.
Main outcome measures: Incidence of impairment on four established cognitive tests, undertaken before, five days, and three months after CABG, examined by three methods for defining impairment.
Results: The three groups were similar with respect to preoperative and intraoperative factors. Observed levels of cognitive impairment were less than had been predicted from previous studies. There was no difference in the groups in cognitive change scores at five days or three months. Group mean analysis showed significant time factors for all four tests but not for interactions or for the lexipafant group. A composite cognitive index, based on the aggregate of four normally distributed tests, showed a significant effect for timing of the test but not for the lexipafant group or interaction. Age, but not duration of bypass, was the most important determinant of postoperative cognitive impairment.
Conclusions: The neuroprotective PAF antagonist lexipafant did not differentially reduce the level of cognitive impairment after CABG as determined by power estimates derived from published studies. The strongest predictors of cognitive impairment were age and timing of the test after operation.
- cerebral dysfunction
- cognitive impairment
- coronary artery bypass graft
- AMIBP, adult memory and information processing battery
- AVLT, auditory verbal learning test
- CABG, coronary artery bypass graft
- CPB, cardiopulmonary bypass
- PAF, platelet activating factor
- TMTB, trail-making test B
- VFT, verbal fluency test
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.